• Mashup Score: 0

    In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers’ primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia Univer

    Tweet Tweets with this article
    • Looking for more #HCT and #celltherapy pharmacy content for #NationalPharmacyWeek? Check out this recent episode of ASTCT Talks, "A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors": https://t.co/pMZti2BKfr @xnyerin https://t.co/PgZ1haE7jn

  • Mashup Score: 0

    Masetti R, Leardini D, Muratore E, et al. Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as Predictor of Mortality in Children. Blood. 2023; (doi:…

    Tweet Tweets with this article
    • An analysis of pre-transplantation (pre-HCT) gut microbiota diversity found a correlation with improved overall survival and fewer occurrences of acute graft-versus-host disease among pediatric patients. Read more on Nucleus: https://t.co/DCYuF0gEKN #GVHD #HCT https://t.co/fvpNE04Ubb